Filing Flows › Concentrix (CNXC) › Stock forecast & fair value
Concentrix (CNXC) stock forecast and fair value
Concentrix (CNXC) trades at $30.52. 5 analysts' median price target is $30.00 (-2%), from $29.00 to $45.00. Across 14 valuation methods the middle fair value is $125.08 (+310%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $194.89 | $362.99 | $584.82 | 12× |
| EV/Sales vs peers, weighted | $403.30 | $738.13 | $2,456.76 | 24× |
| EV/Sales vs peers, matched | $129.37 | $350.91 | $941.79 | 11× |
| EV/Sales vs peers, growth & margin adjusted | $81.23 | $152.42 | $259.40 | +399% |
| Residual income | −$23.49 | −$23.83 | −$24.18 | -178% |
| Analysts' price targets | $29.00 | $32.60 | $45.00 | +7% |
| Shareholder yield (dividends + buybacks) | $49.03 | $55.27 | $63.32 | +81% |
| Tangible book (asset value) | $0.00 | $0.00 | $0.00 | — |
| Survival-weighted value | $138.07 | $257.17 | $414.32 | +743% |
| Stage-weighted value (decline / turnaround) | $101.78 | $189.57 | $305.43 | +521% |
Concentrix's latest quarter
Concentrix, Q3 FY26: revenue $2.5B (-1% year over year), operating margin -37.1%, net loss $988M, operating cash flow $268M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CNXC stock?
The median of 5 analysts' 12-month targets is $30.00, -2% from $30.52; the range is $29.00 to $45.00. The average rating is buy.
What is Concentrix's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$23.83 and $738.13, with a middle value of $125.08 against a price of $30.52. Each method's assumptions are on the page.
Does Concentrix usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is CNXC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.